Breast cancer brain metastases localization and risk of hydrocephalus: a single institution experience

Travers, Sarah; Fisher, Christine M.; Kabos, Peter; Cittelly, Diana M.; Ormond, D. Ryan

doi:10.1007/s11060-023-04314-6

Cited by 2 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BrM sites were most frequently located in the cerebellum (32.7%), consistent with a previous study. 31 Most patients (82.6%) had a KPS score >70 points. After surgery, a large proportion of the patients underwent systemic therapy (85.7%) or radiotherapy (75.5%).…”

Section: Resultsmentioning

confidence: 97%

Density of tertiary lymphoid structures predicts clinical outcome in breast cancer brain metastasis

Zhao,

Fan,

Tao

et al. 2024

J Immunother Cancer

View full text Add to dashboard Cite

BackgroundPatients with breast cancer brain metastases (BCBM) experience a rapid decline in their quality of life. Recently, tertiary lymphoid structures (TLSs), analogs of secondary lymphoid organs, have attracted extensive attention. However, the potential clinical implications of TLSs in BCBMs are poorly understood. In this study, we evaluated the density and composition of TLSs in BCBMs and described their prognostic value.MethodsClinicopathological data were collected from 98 patients (2015–2021). TLSs were evaluated, and a TLS scoring system was constructed. Differences in progression-free survival (PFS) and overall survival (OS) between groups were calculated using the Kaplan-Meier method. Immunohistochemistry and multiplex immunofluorescence (mIF) were used to assess TLSs heterogeneity.ResultsTLSs were identified in 47 patients with BCBM. High TLSs density indicated favorable survival (OS, p=0.003; PFS, p<0.001). TLS was positively associated with OS (p=0.0172) and PFS (p=0.0161) in the human epidermal growth factor receptor type 2-positive subtype, and with prolonged OS (p=0.0482) in the triple-negative breast cancer subtype. The mIF results showed significant differences in the percentages of T follicular helper (Tfh) cells, M2 macrophages, cytotoxic T lymphocytes, and CD8+TIM-3+T lymphocytes between the groups of TLS scores 0–3 (cytotoxic T lymphocytes, p=0.044; Tfh, p=0.021; M2 macrophages, p=0.033; CD8+TIM-3+T lymphocytes, p=0.018). Furthermore, novel nomograms incorporating the TLS scores and other clinicopathological predictors demonstrated prominent predictability of the 1-year, 3-year, and 5-year outcomes of BCBMs (area under the curve >0.800).ConclusionOur results highlight the impact of TLSs abundance on the OS and PFS of patients with BCBM. Additionally, we described the immune composition of TLSs and proposed novel nomograms to predict the prognosis of patients with BCBM.

show abstract

Section: Resultsmentioning

confidence: 97%